Tolmar is committed to protecting your personal privacy. We handle personal information with the utmost respect and assure that all information submitted on the Tolmar site will remain strictly confidential. Tolmar requires that any person or organization providing products and/or services to our clients on our behalf protect the confidentiality of Tolmar’s customer information.
Unless Tolmar receives written permission from an individual, we will not:
The Tolmar site collects only information provided “voluntarily” when using or registering with us on this site. Such information may include:
The information gathered from each client is used internally to process proposals, ensure proper billing, service an account and offer other employment related products that may better serve your needs.
This privacy policy applies only to the information that is collected on Tolmar’s website. It does not apply to any information collected through other methods or sources, including sites owned or operated by our affiliate business partners.
Tolmar works closely with affiliated businesses partners that may have links on our website. Please remember that when you use a link to go from Tolmar’s website to another website, our Privacy Policy no longer applies.
Any browsing and interaction on any third party’s website, including any site that has a link on Tolmar’s website, is subject to the policies and rules of that website.
Tolmar reserves the right to change, modify, or amend our privacy policy as needed; we intend to maintain a policy that is at the forefront of privacy and security principles. Tolmar takes privacy matters seriously; if there are any changes to our privacy policy statement, we will place an updated version on this page. Tolmar encourages site users and visitors to check our privacy policy regularly to stay informed of any policy updates or changes.
Thank you for choosing Tolmar. We appreciate your business and the opportunity to serve you.
If you have any questions, concerns or comments regarding this privacy policy, please feel free to contact Tolmar at:
Tolmar, Inc
701 Centre Ave
Fort Collins, CO 80526
970-212-4500
1-877-4Tolmar (1-877-486-5627)
If you are a California resident, the information below may apply to you in addition to our Privacy Policy. This below information uses certain terms that have the meanings given to them by the California Consumer Privacy Act.
We only share your personal information with the categories of third parties for the business and commercial purposes described below. We do not sell or rent personal information to third parties, including for their own marketing purposes.
During the past 12 months, we may have:
a. Collected the following categories of personal information about you:
b. Collected personal information about you for the following business or commercial purposes:
c. Shared your personal information with the following categories of third parties:
d. Disclosed for a business purpose the following categories of personal information about you:
Subject to certain exceptions, California residents have the right to make the following requests, at no charge, up to twice every 12 months:
We will not discriminate against you for exercising these rights.
Submitting Requests. To exercise your rights please submit a request, or have an authorized agent submit a request on your behalf, to info@tolmar.com or call the following toll-free telephone number 1-844-4TOLMAR. We will respond to your request consistent with applicable law.
RUBRACA® (rucaparib) is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/
or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.
The duration of RUBRACA treatment prior to the diagnosis of MDS/AML ranged from < 2 months to approximately 72 months. The cases were typical of secondary MDS/
cancer therapy-related AML; in all cases, patients had received previous platinum-containing chemotherapy regimens and/
or other DNA damaging agents.
In TRITON3, MDS/AML occurred in 2 out of 201 patients (1%) with a BRCA mutation treated with RUBRACA. The duration of therapy with RUBRACA in patients who developed secondary MDS/cancer therapy-related AML varied from 1.4 to 2.3 years.
Do not start RUBRACA until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood counts for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities (> 4 weeks), interrupt RUBRACA or reduce dose and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks or if MDS/AML is suspected, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.
If MDS/AML is confirmed, discontinue RUBRACA.
Most common adverse reactions of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON3 (≥10%, Grade 1-4) were fatigue/asthenia (61%), musculoskeletal pain (53%), nausea (51%), decreased appetite (34%), diarrhea (31%), constipation (31%), vomiting (25%), dyspnea (19%), dysgeusia (18%), edema (18%), abdominal pain (17%), dizziness (16%), weight decreased (16%), rash (13%), headache (12%), peripheral neuropathy (12%), photosensitivity reaction (12%), and urinary tract infection (10%).
Most common adverse reactions of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia (62%), nausea (52%), decreased appetite (28%), rash (27%), constipation (27%), vomiting (22%), and diarrhea (20%).
Most common laboratory abnormalities of patients with BRCA-mutated mCRPC treated with RUBRACA in TRITON2 (≥ 35%; Grade 1-4) were increased ALT (69%), decreased leukocytes (69%), decreased phosphate (68%), decreased absolute neutrophil count (62%), decreased hemoglobin (59%), increased alkaline phosphatase (44%), increased creatinine (43%), decreased lymphocytes (42%), increased triglycerides (42%), decreased platelets (40%), and decreased sodium (38%).
If concomitant administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing the frequency of international normalized ratio (INR) monitoring.
For medical information inquiries within the U.S., contact pharma& at medinfo.us@pharmaand.com.
You may report adverse events to the FDA at 1-800-FDA-1088 or www.fda.gov/
medwatch.
Alternatively, to report an adverse event or reaction, contact pharma& at pv@pharmaand.com.
To report a product complaint, contact pharma& at complaints@pharmaand.com.
Please see full Prescribing Information for RUBRACA.
for the treatment of BRCA-mutated mCRPC1
Learn more about the updated indication in the full Prescribing Information
ARPI, androgen receptor pathway inhibitor; BRCA, BReast CAncer gene; mCRPC, metastatic castration-resistant prostate cancer;
PARPi, poly (adenosine diphosphate-ribose) polymerase inhibitor.
REFERENCES: 1. RUBRACA (rucaparib). Prescribing Information. pharmaand GmbH. 2025. 2. Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719-732.
